The results of a new study show that the immunotherapy pembrolizumab reduces the risk of tumor recurrence in people with high-risk melanoma when used before and after surgery. Janice Mehnert, MD, associate director of clinical research at NYU Langone Health’s Perlmutter Cancer Center, talks with SurvivorNet about the study and what it means for people with high-risk melanoma.
“It’s important that patients and physicians are aware of this study as it represents a new potential standard of care,” says Dr. Mehnert, also a professor in the Department of Medicine at NYU Grossman School of Medicine. “For patients with high-risk disease, delivering immunotherapy before surgery must be considered.”
Read more from SurvivorNet.